DYAI
Dyadic International, Inc. NASDAQ Listed Jan 16, 2008$0.88
After hrs
$0.85
-3.40%
Mkt Cap $28.7M
52w Low $0.68
25.7% of range
52w High $1.47
50d MA $0.96
200d MA $0.89
P/E (TTM)
-4.1x
EV/EBITDA
—
P/B
23.3x
Debt/Equity
4.1x
ROE
-597.6%
P/FCF
-5.0x
RSI (14)
23.40
ATR (14)
$0.12
Beta
1.21
50d MA
$0.96
200d MA
$0.89
Avg Volume
242.5K
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
140 Intracoastal Pointe Drive · Jupiter, FL 33477-5094 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | AMC | -0.04 | -0.06 | -71.4% | — | — | — | — | — | — | — | — |
| May 13, 2026 | AMC | -0.04 | -0.05 | -25.0% | 0.71 | +1.3% | -2.9% | +4.6% | -0.3% | +0.1% | +2.3% | — |
| Mar 25, 2026 | AMC | -0.03 | -0.06 | -100.0% | 0.87 | -2.6% | -19.6% | -3.2% | +7.5% | +12.3% | +3.9% | — |
| Nov 12, 2025 | AMC | -0.04 | -0.06 | -50.0% | 0.94 | -0.1% | -3.9% | +0.8% | -2.5% | +1.3% | +2.9% | — |
| Aug 13, 2025 | AMC | -0.06 | -0.06 | +0.0% | 0.82 | +4.9% | -2.4% | -6.5% | +6.3% | -0.6% | +2.5% | — |
| May 14, 2025 | AMC | — | -0.07 | — | 1.04 | +1.0% | -4.3% | +4.5% | +1.9% | +0.0% | -2.8% | — |
| Mar 26, 2025 | AMC | -0.04 | -0.05 | -25.0% | 1.33 | +0.0% | +1.5% | +1.5% | -1.5% | +2.2% | +1.4% | — |
| Nov 12, 2024 | AMC | -0.07 | -0.01 | +85.7% | 1.14 | +0.9% | -1.8% | +1.8% | -0.9% | +3.5% | +4.3% | — |
| Aug 13, 2024 | AMC | -0.07 | -0.07 | +0.0% | 1.35 | -3.0% | +0.7% | -2.9% | +0.0% | +1.5% | -1.5% | — |
| May 14, 2024 | AMC | — | -0.07 | — | 1.49 | +1.3% | +5.4% | +5.7% | -0.6% | -2.4% | +3.7% | — |
| Mar 28, 2024 | AMC | -0.07 | -0.08 | -14.3% | 1.67 | +0.6% | +0.0% | +4.8% | +2.9% | +3.3% | -2.7% | — |
| Nov 8, 2023 | AMC | -0.06 | -0.06 | +0.0% | 1.68 | -1.8% | -4.8% | +3.8% | +3.0% | -2.3% | +1.8% | — |
| Aug 9, 2023 | AMC | -0.05 | -0.07 | -40.0% | 1.80 | +1.7% | +10.0% | -2.5% | +4.1% | -10.4% | +3.9% | — |
| May 10, 2023 | AMC | — | -0.03 | — | 1.72 | +1.7% | +10.5% | +2.1% | -0.5% | +3.6% | +5.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.12 | $1.14 | +1.8% | +1.8% | -0.9% | +3.5% | +4.3% | +22.1% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.44 | $1.51 | +4.9% | -2.8% | -1.4% | -0.7% | +0.0% | +8.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.66 | $1.71 | +2.7% | +3.0% | -2.3% | +1.8% | +0.6% | +0.0% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.19 | +0.0% | -0.9% | -5.1% | +6.3% | +1.8% | +2.2% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.86 | $1.84 | -0.8% | -3.8% | -3.9% | -12.2% | +2.0% | +0.0% |
| Jul 18 | Dawson James | Downgrade | Buy → Neutral | — | $3.14 | $3.16 | +0.6% | -9.6% | +3.5% | +3.4% | +0.0% | -1.6% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.77 | -1.1% | -1.8% | -7.3% | -2.7% | +0.4% | -4.8% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.95 | $4.31 | +9.1% | +16.2% | -2.4% | -2.7% | -6.0% | +0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jan 7, 2025 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 15,000 | $2.01 | $30K | 3,375,664 | +9.55% | -3.77% |
| Jan 6, 2025 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 20,000 | $1.92 | $38K | 3,390,664 | +9.55% | -3.77% |
| Dec 30, 2024 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 40,000 | $1.98 | $79K | 3,410,664 | +9.55% | -3.77% |
| Dec 24, 2024 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 5,100 | $1.80 | $9K | 3,450,664 | +9.55% | -3.77% |
| Dec 23, 2024 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 41,143 | $1.84 | $76K | 3,455,764 | +9.55% | -3.77% |
| Dec 20, 2024 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 25,281 | $1.87 | $47K | 3,496,907 | +9.55% | -3.77% |
| Jun 6, 2024 | Francisco Trust under agreement dated February 28, 199610% | — | Sell | 26,340 | $2.43 | $64K | 3,522,188 | +9.55% | -3.77% |
8-K · 2.02
!! High
Dyadic International, Inc. -- 8-K 2.02: Earnings Results
Aug 12
8-K · 8.01
!! High
Dyadic International, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 24
8-K
Dyadic International, Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the filing summary contains only standard SEC boilerplate language without disclosing any substantive business developments or events.
Jun 22
8-K
Dyadic International, Inc. -- 8-K Filing
Jun 18
8-K · 7.01
! Medium
Dyadic International, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 15
8-K · 7.01
! Medium
Dyadic International, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 28
8-K · 2.02
!! High
Dyadic International, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
DYAI faces delisting risk from Nasdaq due to insufficient stockholder equity but has $2.5 million available to regain compliance, creating near-term uncertainty but potential recovery pathway for shareholders.
Mar 30
8-K
Unknown — 8-K Filing
Dyadic is shifting from research-focused to commercially-driven operations with expanded market access, potentially improving revenue growth and path to profitability—critical for biotech valuation and investor returns.
Mar 25
8-K
Dyadic International, Inc. -- 8-K Filing
Dyadic International established an at-the-market offering program allowing flexible common stock sales through a sales agent, providing optional capital raising flexibility without mandatory issuance.
Mar 6
Institutional (13F) — Top 16
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 928,233 | $761K | New | Mar 2026 |
| 2 | Truist Financial Corp | 326,200 | $307K | — | Dec 2025 |
| 3 | Hightower Advisors, Llc | 79,469 | $75K | — | Dec 2025 |
| 4 | Renaissance Technologies Llc | 81,665 | $67K | Reduced | Mar 2026 |
| 5 | Pekin Hardy Strauss, Inc. | 41,745 | $39K | — | Dec 2025 |
| 6 | Northern Trust Corp | 32,851 | $27K | Reduced | Mar 2026 |
| 7 | Inlet Private Wealth, Llc | 30,000 | $25K | — | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 25,925 | $21K | New | Mar 2026 |
| 9 | Commonwealth Equity Services, Llc | 22,579 | $21K | Reduced | Dec 2025 |
| 10 | Captrust Financial Advisors | 15,000 | $12K | — | Mar 2026 |
| 11 | Simplex Trading, Llc | 12,078 | $10K | Added | Mar 2026 |
| 12 | Morgan Stanley | 454 | $426 | Reduced | Dec 2025 |
| 13 | Wells Fargo & Company/mn | 178 | $146 | New | Mar 2026 |
| 14 | Barclays Plc | 72 | $59 | — | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 69 | $57 | — | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 29 | $21 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 141,723 | $110K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 72,188 | $59K | Mar 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 48,866 | $38K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 37,314 | $30K | May 2026 |
| 5 | Fidelity Series Total Market Index Fund | 29,080 | $23K | May 2026 |
Valuation
Market Cap
$28.7M
Enterprise Value
$26.4M
P/E (TTM)
-4.13x
Forward P/E
—
PEG Ratio
-0.28x
P/B
23.28x
P/S
9.65x
P/FCF
-5.03x
EV/EBITDA
—
Shares Out
32.6M
Financials (TTM)
Revenue
$3.0M
Net Income
-$7.3M
EBITDA
-$6.9M
Free Cash Flow
-$5.7M
Op Cash Flow
-$5.7M
EPS Basic
$-0.23
EPS Diluted
$-0.21
EPS Forward
$-0.09
Gross Margin
31.3%
Op Margin
-238.4%
Net Margin
-245.1%
Balance Sheet
Total Assets
$9.9M
Total Liab.
$8.7M
Total Equity
$1.2M
Cash
$7.3M
LT Debt
$5.0M
Book Value/Sh
$0.04
Debt/Equity
4.11x
Current Ratio
2.68
Quick Ratio
2.68
Returns & Growth
ROE
-597.6%
ROA
-74.1%
ROIC
-113.5%
Rev Growth YoY
-11.6%
EPS Growth YoY
-15.0%
Price Returns
2W
-0.9%
1M
-0.9%
3M
+45.3%
6M
+27.3%
12M
+23.5%
Technicals
52W High
$1.47
52W Low
$0.68
50d MA
$0.96
200d MA
$0.89
RSI (14)
23.40
ATR (14)
$0.12
Beta
1.21
Avg Volume
242K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 25, 2026 6:12am
· Source: financialmodelingprep.com